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Abstract
Background: Rotavirus is the most common cause of severe diarrhea leading to hospitalization
or disease-specific death among young children. New rotavirus vaccines have recently been
approved. Some previous studies have provided broad qualitative insights into the health and
economic consequences of introducing the vaccines into low-income countries, representing
several features of rotavirus infection, such as varying degrees of severity and age-dependency of
clinical manifestation, in their model-based analyses. We extend this work to reflect additional
features of rotavirus (e.g., the possibility of reinfection and varying degrees of partial immunity
conferred by natural infection), and assess the influence of the features on the cost-effectiveness of
rotavirus vaccination.
Methods: We developed a Markov model that reflects key features of rotavirus infection, using
the most recent data available. We applied the model to the 2004 Vietnamese birth cohort and re-
evaluated the cost-effectiveness (2004 US dollars per disability-adjusted life year [DALY]) of
rotavirus vaccination (Rotarix®) compared to no vaccination, from both societal and health care
system perspectives. We conducted univariate sensitivity analyses and also performed a
probabilistic sensitivity analysis, based on Monte Carlo simulations drawing parameter values from
the distributions assigned to key uncertain parameters.
Results: Rotavirus vaccination would not completely protect young children against rotavirus
infection due to the partial nature of vaccine immunity, but would effectively reduce severe cases
of rotavirus gastroenteritis (outpatient visits, hospitalizations, or deaths) by about 67% over the
first 5 years of life. Under base-case assumptions (94% coverage and $5 per dose), the incremental
cost per DALY averted from vaccination compared to no vaccination would be $540 from the
societal perspective and $550 from the health care system perspective.
Conclusion: Introducing rotavirus vaccines would be a cost-effective public health intervention in
Vietnam. However, given the uncertainty about vaccine efficacy and potential changes in rotavirus
epidemiology in local settings, further clinical research and re-evaluation of rotavirus vaccination
programs may be necessary as new information emerges.
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Background
Rotavirus is the most common cause of severe diarrhea
leading to hospitalization or disease-specific death among
children under 5 years of age [1,2]. The rotavirus infection
is reported to cause more than 2 million hospitalizations
and about 527,000 deaths annually (as of 2004), and the
burden of disease is higher in developing countries [1].
Human rotavirus infections are characterized by the fol-
lowing features: (1) diverse genotypes that vary geograph-
ically and over time [3-5]; (2) frequently asymptomatic
presentation or non-specific clinical symptoms (e.g., var-
ying degrees of diarrhea, vomiting, or fever); (3) age-
dependency of clinical manifestation (e.g., rotavirus infec-
tions in infants younger than 3 months old are often not
severe) [6]; (4) common reinfections and varying degrees
of protection against subsequent infections depending on
the number of previous infections [7,8]; and (5) seasonal-
ity of incidence (e.g., rotavirus infections peak during the
winter season typically) [9].
Since rotavirus is endemic in both developed and devel-
oping countries, improved hygiene is unlikely to be effec-
tive in reducing rates of infection, prompting great interest
in the development of an effective vaccine [10,11].
Recently, two new oral rotavirus vaccines, Rotarix® and
RotaTeq®, have been approved [11,12]. To inform deci-
sion-makers in countries considering the introduction of
rotavirus vaccine into their national immunization pro-
grams, a number of studies have attempted to quantify the
health and economic impact of these vaccines in different
settings, using model-based approaches [13-24]. Three
studies have evaluated the impact of introducing rotavirus
vaccines in low-income countries in Asia (one each in
Vietnam [13], Uzbekistan [15], and Asia as a whole [14])
where the burden of rotavirus disease is greatest.
Estimating the avertable rotavirus disease burden is chal-
lenging since, despite some known characteristics
described above, many aspects of rotavirus infection
remain unknown. For example, although natural infec-
tions are reported to confer some level of immunity
against subsequent infections, little is known about the
specific nature of such immunity (e.g., relative strength
and length of immunity compared with that from vac-
cines). There is also high uncertainty around the incidence
of infection, as rotavirus infection is often asymptomatic,
and even symptomatic cases can only be diagnosed defin-
itively through laboratory testing, which is not usually
performed even in medical facilities in developed coun-
tries [16]. For these reasons, most previous studies have
estimated the avertable disease burden through vaccina-
tion based only on the estimated incidence of sympto-
matic rotavirus diarrhea (not rotavirus infection itself)
and proportions of severe cases requiring medical treat-
ment or leading to deaths, based on surveillance data [13-
19,23,24]. Further simplifying assumptions are typically:
one episode of rotavirus diarrhea at maximum, and full
protection against subsequent rotavirus diarrhea during
the first 5 years of life of a birth cohort [13-15,17,19,23].
The potential impact of the dimensions that are not incor-
porated in previous models on the cost-effectiveness of
rotavirus vaccines have received less attention thus far.
Such uncertainty may be higher in the studies performed
in low-income country settings, given that surveillance
systems are relatively less comprehensive than in devel-
oped countries and that there are limited data from devel-
oping countries on local vaccine efficacy and safety. For
example, although surveillance systems in some resource-
poor countries provide some information on the inci-
dence of rotavirus gastroenteritis requiring hospitaliza-
tion, attributing outpatient visits to rotavirus infection is
difficult since surveillance programs usually do not
include outpatient clinic settings in those countries. While
there is a concern that vaccine efficacy may be different
from setting to setting partly due to the diversity and var-
iability of rotavirus genotypes, in Asia and Africa Phase III
clinical trials have only been recently initiated, and local
vaccine efficacy and safety data will likely not become
available until 2010 [25]. Indeed, the three studies per-
formed in Asian settings [13-15] have used the efficacy
data from clinical trials performed in other regions such as
Europe or Latin America [26] without adjustment for the
different genotype distribution.
In this paper we aimed to extend previous studies by
developing a more detailed natural history model of rota-
virus infection that uses the best available data, reflects the
key features of rotavirus epidemiology in developing
countries, incorporates reinfection and natural immunity,
and comprehensively explores uncertainty surrounding
these features. We applied the model to Vietnam in order
to reevaluate the cost-effectiveness of a rotavirus vaccina-
tion program in this country.
Methods
Analytic overview
Since our focus was on developing countries, we chose to
evaluate the Rotarix®  vaccine, which is an attenuated
human rotavirus vaccine targeting the highly prevalent
G1P[8] genotype, introduced in 2004 and tested through
phase III clinical trials in some Latin American countries
[26,27]. For our analysis, following the clinical definition
of severe gastroenteritis (an episode of diarrhea requiring
overnight hospitalization or rehydration therapy in a
medical facility) used in a phase III clinical trial of Rotarix®
[26], we assumed that the rotavirus infection leads to one
of the following infection outcomes: asymptomatic, mild
gastroenteritis (requiring home care only), or severe gas-
troenteritis (requiring an outpatient visit or hospitalizationBMC Public Health 2009, 9:29 http://www.biomedcentral.com/1471-2458/9/29
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or leading to disease-specific death). Based on our working
definitions, we constructed a Markov model (TreeAge Pro
2006) that simulates the acquisition of infection, immu-
nity, and resolution of symptoms. We applied the model
to the 2004 Vietnamese birth cohort (N = 1,644,000) [28]
and followed the cohort through age 5 to reevaluate the
cost-effectiveness of introducing the rotavirus vaccine into
Vietnam, from both the societal (base-case) and health-
care system perspectives. We chose Vietnam as our exam-
ple in part because of the availability of epidemiological
and cost data, and in part to compare our results to a pre-
vious study performed in Vietnam [13]. Model outcomes
included cases of outpatient clinic visits and hospitaliza-
tion, rotavirus diarrhea-associated deaths, disability-
adjusted life years (DALYs), and costs incurred during the
first 5 years of life of the cohort. Primary results were
expressed as the incremental cost (2004 US dollars) per
DALY averted of rotavirus vaccination compared to no
intervention. To facilitate the interpretation of cost-effec-
tiveness results, we consider interventions with incremen-
tal cost per DALY averted less than a country's GDP per
capita 'very cost-effective' and interventions with the cor-
responding ratios between 1 and 3-times the GDP per cap-
ita 'cost-effective', as suggested by the World Health
Organization (WHO) [29]. For the base-case, both effec-
tiveness and cost were discounted at 3%. To explore
parameter uncertainty, we performed a multivariate prob-
abilistic sensitivity analysis as well as univariate sensitivity
analyses.
Model
In order to allow rotavirus reinfection, distinguish pri-
mary rotavirus infection from subsequent infections with
different levels of partial immunity, and account for the
timing of vaccination and disease events, the model was
structured as a Markov model with a cycle length of 1
week (the average period between an infection and its res-
olution [30]) over a 5-year time horizon. Figure 1 presents
the schematic and natural history model of rotavirus
infection. We assumed that the immunity conferred by
natural infection or vaccines is imperfect (or partial) so
that resolved infections or vaccination lead to 'partially
immune' status (i.e. immunity does not fully protect
against rotavirus infection but reduces the severity of rota-
virus infection outcomes to some extent). We also
assumed that infants are exposed to rotavirus infection
starting from birth but that infections during the first 2
months (i.e., before the first vaccine dose) are mild or
asymptomatic (probably due to maternal antibodies
[30]), not incurring any treatment costs. Thus, for the first
two months of life before the first vaccine dose, for both
vaccinated and unvaccinated strategies, model outcomes
were dichotomized using a decision tree–susceptible ver-
sus 'infected (partially immune)'–according to whether
infants got infected with rotavirus. At the age of 2 months,
infants were given the first vaccine dose or not according
to each strategy and entered the Markov model, which
includes several health-related states: susceptible; infected
with wild type rotavirus (asymptomatic, mild, and
severe); partially immune after (the first, second, third, or
fourth) natural infections; partially immune by vaccina-
tion; rotavirus diarrhea-specific death; and death due to
other causes (Figure 1). Of the vaccinated infants, unin-
fected infants entered into the "partially immune by vac-
cination" state while previously infected infants entered
into the "partially immune by first infection." Under the
no vaccination strategy, susceptible infants entered the
"Susceptible" state and previously infected infants the
"partially immune by first infection" state. Individuals
then moved between health states according to the natu-
ral history model of rotavirus infection with different
probabilities depending on their vaccination status, age at
infection, number of previous infections, and vaccine effi-
cacy (Table 1). Specifically, the transition probabilities
were estimated based on the following base-case assump-
tions: (1) vaccinated infants received the second dose at
the age of 4 months but the period between the first and
second doses provides the same level of immunity as a
full-dose course (although some clinical trials [31] report
different incidence rates between the inter-dose period
and the period after the 2nd dose, we assumed the same
level of vaccine efficacy for the two different periods since
the evidence from the literature is difficult to interpret);
(2) vaccinated children may face risks of rotavirus infec-
tion due to the imperfect nature of vaccine immunity, but
given the same number of previous infections, their risk of
infection and proportion experiencing severe rotavirus
gastroenteritis are lower than in unvaccinated children
[31,32]; (3) for both vaccinated and unvaccinated chil-
dren, subsequent infections have lower incidence rates
and less severe outcomes compared with preceding infec-
tions (e.g., the proportion of severe cases caused by a sec-
ond infection is lower than that by a primary infection
and subsequent infections after the second one do not
lead to severe cases [8]) (Table 1); and (4) immunity from
either natural infection or vaccination lasts over the full
time horizon of 5 years, but the level of immunity
depends on the number of previous infections. We
explored the impact of waning vaccine-induced immunity
in sensitivity analyses.
The model tracked the cumulative numbers of different
types of rotavirus infection outcomes over the time hori-
zon of 5 years. The model then translated the disease out-
comes into DALYs following the standard Global Burden
of Disease (GBD) approach [33]. Health losses associated
with nonfatal outcomes (i.e., outpatient clinic visits or
hospitalizations) were calculated using the disability
weights of 0.119 for an episode of diarrhea in general
from the GBD study and assuming a duration of 6 daysBMC Public Health 2009, 9:29 http://www.biomedcentral.com/1471-2458/9/29
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Model schematic Figure 1
Model schematic. This figure presents the schematic of the natural history of rotavirus infection. Natural infection by wild 
type rotavirus can provide protection against subsequent infections with a varying degree of immunity depending on the 
number of previous infections as well as ages at infection.
Birth Age 0 month 
Disease-specific death
Outpatient visit
Hospitalization 
Death
Markov
model 
No Vaccination  Vaccination
Decision
tree
4th infection 
3rd infection 
2nd infection 
1st infection 
Infected before 
vaccination
(partially immune)
(3%)
Not infected
before vaccination 
(susceptible) 
(97%)
Not infected
before vaccination 
(susceptible) 
(97%)
Infected before 
vaccination
(partially immune)
(3%)
Asympto-
matic
Severe Mild
Susceptible 
(no diarrhea)
No vaccination  Vaccination (dose 1&2: age 2&4 months)
Partially immune 
due to vaccination 
Partially immune
(no diarrhea) 
Asympto-
matic
Mild Severe
Partially immune
(no diarrhea) 
Asympto-
matic
Mild
Partially immune
(no diarrhea) 
Asympto-
matic
Mild
Age 2 months 
Outpatient visit 
Hospitalization 
Death
Disease-specific death 
The solid arrows 
represent transition 
probabilities between 
health states, which 
are different depending 
on vaccination history 
and the number of 
previous wildtype 
rotavirus infections 
(Table 1). 
Age 60 months  * Deaths due to other causes occur at every stage according to the local background mortality but are not shown.BMC Public Health 2009, 9:29 http://www.biomedcentral.com/1471-2458/9/29
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Table 1: Model input parameter values and ranges
Parameters Baseline estimates Rangesa Distributionsb Sources
Epidemiological parameters
5-year cumulative numbers of rotavirus gastroenteritis death 
(for a 2004 birth cohort)
1,673 1,514–1,833c Not varied [38]
Estimated age-specific incidence rate of rotavirus diarrhea associated deaths 
(per 100,000 per month)d
Not varied [37] Estimated
age 0–1 month 0.0 Not varied
age 2 months 3.5 2.8–4.2
age 3–5 months 3.8 3.0–4.5
age 6–8 months 6.5 5.2–7.8
age 9–11 months 12.2 9.7–14.6
age 12–14 months 15.3 12.2–18.3
age 15–17 months 14.0 11.2–16.8
age 18–23 months 7.9 6.3–9.5
age 24–35 months 3.4 2.7–4.1
age 36–47 months 2.9 2.3–3.5
age 48–59 months 2.6 2.1–3.1
Cumulative probability of primary infection (by 2 months of age), % 3 0–8 Not varied Estimated
Ratio of numbers of hospitalizations to deaths attributable to rotavirus 
gastroenteritis
20.7 10.35–31.05 Not varied [13]
Ratio of numbers of outpatient visits to deaths attributable to rotavirus 
gastroenteritis
96.6 32.2–103.0 Not varied Assumed
Ratios of annual incidence of different rotavirus infection outcomes 
(without vaccination)
Primary infections
- mild vs. severe casese 4.3 2.15–6.45 Not varied [8]
- asymptomatic vs. severe casese 4.1 2.05–6.15 Not varied [8]
Secondary infections
- mild vs. severe casese 21.5 10.8–32.3 Triangular [8]
- asymptomatic vs. severe casese 19.0 9.5–28.5 Triangular [8]
Secondary vs. primary severe infections 0.167 0.125–0.209 Not varied [8]
Tertiary vs. primary 'any' infectionsf 0.478 0.239–0.717 Triangular [8]
Quaternary vs. primary 'any' infectionsf 0.372 0.186–0.558 Triangular [8]
Vaccine characteristics
Vaccine coverage (2 doses) 94 90–98 Triangular [13]
Serotype-specific vaccine efficacy (against severe gastroenteritis), % Not varied
G1P[8] 90.8 70.5–98.2c [26]
G3P[8], G4P[8], G9P[8] 86.9 62.8–96.6c [26]
G2P[4] and other combinations of G and P 45.4 0–85.6 [26]
Vaccine efficacy against severe gastroenteritis, % 
(adjusted for the serotype distribution)
77 43–99 Triangular Estimated
Vaccine efficacy against mild gastroenteritis, % 
(not adjusted for the serotype distribution)
41 21–62 Triangular Estimated
Costsg
Vaccination costs
Vaccine price (per dose) 5 0.1–10 Triangular Assumed
Vaccine wastage rate, % 10 0–20 Triangular Assumed
Delivery costsh (per dose) 0.7 0.35–1.05 Triangular Estimated
Disease treatment costs
Outpatient visit (per episode) 3.49 2.88–4.11 Triangular [13]
Hospitalization (per episode) 19.97 14.98–24.96 Triangular [13]
Direct nonmedical costs
Transport
- for outpatient visit 0.69 0.52–0.86 Triangular [13]
- for hospitalization 4.46 3.35–5.58 Triangular [13]
Caregiver's time
- for outpatient visit 2.82 2.12–3.53 Triangular [13]
- for hospitalization 7.86 5.90–9.83 Triangular [13]BMC Public Health 2009, 9:29 http://www.biomedcentral.com/1471-2458/9/29
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[19]. For the base-case, we did not weight healthy years
lived differentially by age, but we did consider age-weight-
ing in a sensitivity analysis for comparability with previ-
ous studies.
Model input
Vaccine efficacy
To estimate the vaccine's efficacy against rotavirus gastro-
enteritis in Vietnam, we used the serotype-specific efficacy
data of Rotarix® from the clinical trials performed in Latin
American countries (Table 1) [26], and computed an aver-
age efficacy based on Vietnam's distribution of rotavirus
genotypes. Genotypes of rotavirus are determined by an
independent combination of two different groups of pro-
teins, G and P, with the 5 most prevalent genotypes world-
wide being G1P[8], G1P[8], G2P[4], G3P[8], G4P[8], and
G9P[8][34]. According to recently published sentinel hos-
pital surveillance data for 1998–2003 [35], the genotype
distribution of rotavirus in Vietnam is as follows: G1P[8]
(44.5%), strains sharing only P[8] with the vaccine (i.e.,
G3P[8], G4P[8], or G9P[8]) (26.3%), strains sharing only
G1 (2.6%), and strains sharing neither antigen (e.g.,
G2P[4]) (26.6%). The serotype-adjusted efficacy against
severe rotavirus infection was 77%. We assumed an aver-
age vaccine efficacy of 41% against mild rotavirus infec-
tions based on published literature [8]. In a sensitivity
analysis on waning vaccine-induced immunity, we
assumed that vaccine efficacy against severe cases would
decline during each of the first 5 years of life. In the
absence of direct evidence on waning immunity, we
applied a conservative estimate of declining vaccine effi-
cacy over age by extending the 2-year efficacy data from
Linhares et al.'s study [36] among Latin American infants.
The resulting vaccine efficacy estimates (adjusted for sero-
type distribution) for the first 5 years of life were as fol-
lows: 77%, 66%, 57%, 49%, and 43% for age 0, 1, 2, 3,
and 4, respectively.
Vaccine coverage
Since rotavirus vaccines can be administered with other
traditional childhood vaccines [10], we assumed that
rotavirus vaccines are administered in Vietnam together
with the first and second doses of diphtheria-tetanus-per-
tussis (DTP) vaccine. The coverage for the first two doses
of the DTP vaccine in Vietnam was about 94% and 93%,
respectively, in 2004 [13]. For simplicity, we assumed that
infants who received the first dose would also complete
the second dose, using 94% coverage for the base-case.
Incidence of rotavirus infection
We assumed that most children in Vietnam experience
rotavirus infection through the fecal-oral route by the age
of 5 [37]. We obtained data on cumulative age distribu-
tion of hospitalized children due to rotavirus gastroenteri-
tis in Vietnam (under no vaccination) from a published
study that reports sentinel surveillance data [37] (Table
1). Because similar data are not available for outpatient
visits or deaths due to the virus, for the two forms of severe
cases, we assumed the same cumulative age distribution
as the one for hospitalization. For unvaccinated children,
age-specific, rotavirus-associated mortality rates were esti-
mated by applying the cumulative age distribution to the
World Health Organization (WHO) estimate of the total
number of rotavirus-associated deaths among Vietnamese
children aged < 5 years in 2004 [38] (Table 1). Age-spe-
cific incidence rates of rotavirus-associated hospitaliza-
tion were calculated by applying the estimated rotavirus-
associated mortality to the ratio of the projected cases of
rotavirus-associated hospitalization and rotavirus
diarrhea-specific deaths (~21:1), which was obtained
from a previous study in Vietnam [13] (Table 1). The inci-
dence of outpatient visits was estimated using the same
approach, but the corresponding ratio was adjusted in the
model to improve internal consistency (i.e., the value of
the ratio parameter was varied over a plausible range and
adjusted so that the model projected the cumulative prob-
ability of rotavirus infection, and the age distribution of
the severe cases were consistent with the model input and
assumptions). Similarly, the incidence rates of mild and
asymptomatic infections were derived by applying the
above estimated incidence of severe cases (i.e., aggregate
incidence of rotavirus-specific deaths, hospitalizations,
Discount rate, % 3 0–6 Not applicable Assumed
Disability weight for diarrhoeal episode 0.119 0.086–0.152 Triangular [47]
a This column shows the ranges of parameters that were varied during one-way sensitivity analyses.
b This column shows parameters that were varied during the probabilistic sensitivity analysis and distributions assigned to them. Since data often 
did not contain enough information from which to estimate distribution parameters, triangular distributions were chosen for all parameters.
c 95% confidence interval.
d Monthly incidence rates were converted to weekly transition probabilities within the model, assuming an exponential relationship between the 
cumulative incidence at different time (age) intervals and time (age). For details, see Additional file 1, which provides a more detailed explanation of 
the steps taken.
e 'Severe cases' means the aggregate number of outpatient visits, hospitalization, or disease-specific deaths attributable to rotavirus gastroenteritis.
f 'Any' infection includes severe cases, mild cases, and asymptomatic cases.
g All costs are expressed in 2004 US dollars.
h Delivery cost is defined as any costs incurred in distributing and administering vaccines (other than costs for vaccine purchase), including all capital 
costs (e.g., cold chains and vehicles) and shared operational costs (e.g., salary for personnel, transportation, maintenance, training, social 
mobilization, and surveillance).
Table 1: Model input parameter values and ranges (Continued)BMC Public Health 2009, 9:29 http://www.biomedcentral.com/1471-2458/9/29
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and outpatient visits) to the ratios of each infection out-
come's incidence to the severe outcome's incidence,
which were estimated from findings of a cohort study that
followed Mexican children up to 2 years of age and pro-
vided incidence rates of various rotavirus infection out-
comes (overall, severe, mild, and asymptomatic
infections) differentiated by the number of previous infec-
tions [8] (Table 1). Based on the findings of the same
cohort study [8], we assumed that approximately 86% of
the aggregate number of severe cases would occur among
primary infections and the rest among subsequent infec-
tions, and the related incidence rates were adjusted corre-
spondingly. Varying degrees of partial immunity by
natural infection were reflected in the incidence of various
infection outcomes differentiated by the number of previ-
ous infection [8]. The corresponding incidence rates
among vaccinated children were back-calculated using the
formula for calculating vaccine efficacy, (1-relative risk) ×
100. More details on these calculations are provided in
Additional file 1.
Costs
Adopting a societal perspective in the base-case analysis,
we included direct medical costs, which consist of pro-
gram costs (vaccine and delivery costs) and medical treat-
ment costs, and direct non-medical costs (travel costs,
caregivers' time spent caring for sick children). In our
analysis conducted from the health care system perspec-
tive we included direct medical costs only. All costs were
expressed in 2004 US dollars. To estimate vaccine costs,
we used an ingredients approach, multiplying the annual
number of units of resources consumed by their unit price
[39]. Currently, the price of Rotarix® has not yet been set
in any developing countries. However, given the manufac-
turer's stated commitment to differential pricing for devel-
oping countries and the recently agreed tiered price of $7/
dose in Brazil, a middle-income country with GDP per
capita of about $8,000, there is a possibility that the vac-
cine price per dose in developing regions might be set
lower than $7 [40]. Thus, for the base case, we used the
price of $5 per dose (Table 1). We assumed a 10% wastage
rate of vaccine but did not consider reserve stock [39]. We
estimated delivery costs (defined in our analysis as any
costs incurred in distributing and administering vaccines
other than the cost of the vaccine itself) using the per-dose
delivery cost projected for 2004 in the Vietnamese
Expanded Program of Immunization (EPI) program
budget [41] and multiplying the estimates by the number
of doses for a complete course of Rotarix® (Table 1). We
obtained data for direct medical (other than program
costs) and non-medical costs from Fischer et al.'s study
[13], which provides comprehensive estimates of disease-
specific treatment costs and caregivers' time and travel
costs for different levels of health facilities in rural versus
urban areas in Vietnam [42,43]. We estimated the
national-level average for each cost item, by calculating a
weighted mean of the estimates reported by Fischer et al.,
accounting for the rural (75%) and urban (25%) break-
down in Vietnam [13] (Table 1). We did not consider the
costs for treating adverse events since the adverse events
attributable to rotavirus vaccines are reported to be negli-
gible [26].
Uncertainty analysis
To explore uncertainty around parameters, we conducted
univariate sensitivity analysis over the plausible ranges of
key parameters (Table 1). As an extension of the univari-
ate sensitivity analysis we performed a threshold analysis
to identify the maximum per-dose vaccine price at which
vaccination would still have a cost-effectiveness ratio
below the per-capita GDP in Vietnam. We also performed
a multivariate, probabilistic sensitivity analysis each per-
spective, based on 10,000 Monte Carlo simulations (Tree-
Age 2006) drawing parameter values from the
distributions specified in Table 1. The results were used to
construct a cost-effectiveness acceptability curve from
each perspective.
Results
Health outcomes
In the absence of vaccination, 58% of infants would get
infected during the first year of life. With 94% vaccination
coverage, approximately 47% of children would get
infected with rotavirus (including asymptomatic infec-
tions) before age 5, and the incidence of severe cases of
rotavirus gastroenteritis would be reduced by about 67%.
Both vaccinated and unvaccinated children would experi-
ence about two rotavirus infections on average (~2.0
times for vaccinated and ~2.3 times for unvaccinated chil-
dren) by 5 years of age. Assuming 94% coverage, vaccinat-
ing a cohort of 1,644,000 Vietnamese infants would
prevent 105,300 outpatient visits, 22,600 hospitaliza-
tions, and 1,090 premature deaths attributable to rotavi-
rus infection over a five year period, compared to no
intervention (undiscounted) (Table 2). Figure 2(upper
panel) shows the estimated cumulative probabilities of
the first, second, third, and fourth infections, which have
a similar pattern to the ones reported in the previously
published cohort study [8]. Figure 2(lower panel)
presents the cumulative age-distribution of hospitalized
cases, which is closely fitted to the observed data [35].
Translating the health outcomes into summary measures
of healthy life, vaccination would avert 31,600 DALYs
(discounted at 3% per annum) (Table 2).
Cost-effectiveness: base-case analysis
Assuming a vaccine price of $5 per dose (with 10% wast-
age) and 94% coverage, the average vaccination cost per
vaccinated child with 2 doses of rotavirus vaccine would
be $11.10, and the total program costs for the 2004 birthBMC Public Health 2009, 9:29 http://www.biomedcentral.com/1471-2458/9/29
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cohort would be $18.2 million. From the societal perspec-
tive, accounting for medical treatment costs and direct
non-medical costs in addition to the program costs, the
total costs were $19.0 million with vaccination and $2.0
million without vaccination. From the health care system
perspective, considering direct medical costs only, the cor-
responding total lifetime costs were $18.6 million and
$1.2 million, respectively. Accordingly, combining both
health and cost outcomes, the estimated incremental cost
per DALY averted of routine vaccination would be $540
from the societal perspective and $550 from the health
care system perspective (Table 2).
Uncertainty analysis
In univariate analyses, results were most sensitive to vac-
cine price, vaccine efficacy against severe gastroenteritis,
and discount rate (Figure 3). For example, when the vac-
cine unit price was set at $1, the incremental cost-effec-
tiveness was $100/DALY averted, but the corresponding
value was $1,080/DALY averted with a vaccine price of
$10 per dose. The corresponding ratio was $755/DALY
averted when the price was set at $7 per dose (which is the
recently agreed tiered price of Rotarix® in Brazil). In the
threshold analysis for the vaccine price, the program
would be cost-effective based on a benchmark of $580/
DALY averted (equal to the per-capita GPD of Vietnam) at
prices up to $5.41 per dose, and would be cost-effective
based on a benchmark of $1,740/DALY averted (three
times GDP per-capita) at prices up to $32.4 per dose.
When vaccine efficacy against severe rotavirus gastroen-
teritis was varied between 43% and 99%, the incremental
cost-effectiveness ratio ranged from $1,200 to $410 per
DALY averted. With no discounting, the incremental cost-
effectiveness ratio was $220/DALY averted; with a dis-
count rate of 6% the ratio increased to $960/DALY
averted. Results were moderately sensitive to rotavirus-
associated mortality, waning vaccine-induced immunity,
and vaccine wastage rate. If vaccine-induced immunity
waned over five years, corresponding to a decline in age-
specific vaccine efficacy from 77% in year 1 to 43% in year
5, the incremental cost per DALY changed by approxi-
mately 15%, increasing from $540 (base-case assuming
no waning) to $630. The general results were also robust
to delivery cost, cost per hospitalization or outpatient
visit, and the disability weight for diarrhea (Figure 3).
Selected model-predicted health outcomes Figure 2
Selected model-predicted health outcomes. The 
upper panel presents the cumulative probabilities of the pri-
mary and subsequent rotavirus infections over time under no 
vaccination. The lower panel shows the cumulative age distri-
bution of hospitalized cases associated with rotavirus gastro-
enteritis (observed data versus model estimates).
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Table 2: Base-case results
Societal perspective Healthcare system perspective
No vaccination Routine vaccination No vaccination Routine vaccination
Total cases of outpatient visits (thousands) 158.0 52.7 158.0 52.7
Total cases of hospitalization (thousands) 33.9 11.3 33.9 11.3
Total cases of premature deaths 1,640 550 1,640 550
Cost (2004 $) (thousands) 1,973 18,906 1,151 18,577
Incremental cost (2004 $) (thousands) -- 16,933 -- 17,462
Effectiveness (DALYs) (thousands) 1,887 1,856 1,887 1,856
Incremental effectiveness (DALYs averted) (thousands) -- 31.6 -- 31.6
ICER ($/DALY averted) -- 540 -- 550
DALY: disability-adjusted life year. ICER: incremental cost-effectiveness ratioBMC Public Health 2009, 9:29 http://www.biomedcentral.com/1471-2458/9/29
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Figure 4 presents the results of multivariate uncertainty
analysis in the form of a cost-effectiveness acceptability
curve from each perspective. The curve from the societal
perspective shows that the probabilities that the program
would be cost-effective are 50%, 75%, and 100% at
thresholds of 530, $710, and $1,350 per DALY averted,
respectively.
Discussion
The epidemiology of rotavirus infection has been consid-
ered relatively simple compared to that of other patho-
gens with multiple transmission routes (e.g., HIV, human
papilomavirus, or hepatitis B virus), although many
aspects of rotavirus natural history are unknown and
uncertain. Thus, most previous studies have evaluated the
impact of rotavirus vaccines using a simple static model,
not fully incorporating all key features of rotavirus infec-
tion, and the potential impact of the features that are not
incorporated in the models has remained unexplored.
Being motivated in part to examine such impact on the
cost-effectiveness of rotavirus vaccines in low-income
countries, we developed a Markov model that allows
more flexibility in reflecting the key features of rotavirus
infection and exploring the uncertainty surrounding
them. With a time interval that approximately corre-
sponds to an episode of rotavirus infection, our model
explicitly considers the timing of events and, unlike previ-
ous studies performed in low income country settings,
allows for reinfections (up to four), taking into account
partial immunity by wildtype infection that varies
depending on the number of previous infections.
As such, our model enables more detailed simulations of
the natural history and epidemiology of rotavirus. Our
model tracks the number of children who experience dif-
ferent numbers of rotavirus infections over time, and thus
provides cumulative probabilities (e.g., Figure 2, upper
panel) of various types of infection outcomes and cumu-
lative age distribution (e.g., Figure 2, lower panel) as well
as overall cases of health outcome measures (Table 2).
Our results show that children may get infected with
wildtype rotarivus multiple times over the 5-year horizon,
but that a majority (~84% under the base-case assump-
tions) of severe gastroenteritis would occur during the first
infection. Our results also show that about 20% of infants
would experience rotavirus infection by 6 months of age
(Figure 2, lower panel). These findings reaffirm the
importance of a strict adherence to the recommended
immunization schedule (2 and 4 months of age) once
rotavirus vaccines are introduced. Further, it is noteworthy
that the model-predicted percentage of reduction in severe
cases, 67%, is lower than the initially assumed average
vaccine efficacy, 77%, but is a more realistic assessment of
the avertable disease burden since it was predicted using
the model incorporating more realistic coverage, compet-
ing mortality, and age-dependency of disease severity.
When we added vaccine effects to the natural history
model, our results suggest that, although the rotavirus vac-
cine would not completely protect against rotavirus infec-
Selected results of one-way sensitivity analyses Figure 3
Selected results of one-way sensitivity analyses. This 
graph presents selected results of univariate sensitivity analy-
ses from the societal perspective. The x-axis represents the 
ranges of the incremental cost-effectiveness ratios of infant 
rotavirus vaccination in Vietnamese children when the base-
line estimates of several key parameters were varied over 
plausible ranges. The vertical line represents the base case 
incremental cost-effectiveness ratio of rotavirus vaccination.
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Cost-effectiveness acceptability curves Figure 4
Cost-effectiveness acceptability curves. This figure 
summarizes the results of probabilistic sensitivity analysis 
from the societal perspective. The curve shows the probabil-
ities that rotavirus vaccination is cost-effective at varying 
cost-effectiveness threshold ratios.
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tion itself due to the imperfect nature of vaccine immunity
and common rotavirus infection in Vietnam, infant vacci-
nation would significantly reduce the disease burden of
severe gastroenteritis caused by the virus. Under the base-
case assumptions, the incremental cost per DALY averted
was $540 from the societal perspective. The value is higher
than those of many other traditional childhood vaccines
administered in developing regions (e.g.,~$30 [in 2000
international dollars] per DALY averted for measles vacci-
nation with 80% coverage in sub Saharan region [44]),
but is still close to Vietnam's 2006 GDP per capita of
about $580 (2004 US dollars) [45], which is used as a
cost-effectiveness threshold in our analysis [29]. Accord-
ingly, our findings show that a rotavirus vaccination pro-
gram may be considered very cost-effective in Vietnam
based on the commonly used GDP per capita benchmark
[29].
When compared to a previous study performed by Fischer
and colleagues in the same setting [13], our model's point
estimate of the cost per DALY averted is approximately 6-
fold higher than the corresponding value estimated by
Fischer et al., of $87/DALY averted (in 2004 US dollars,
assuming a societal perspective and a vaccine price of $5
per dose; calculated based on the incremental costs and
effectiveness from the societal perspective reported in
Table 3 in Fischer et al.'s study [13]). Given that we
obtained most cost data from Fischer et al.'s study making
very similar assumptions on resource use, some possible
sources of the discrepancy include that: (1) for 5-year
cumulative number of rotavirus associated deaths, we
used a more recent WHO estimate which was much lower
than the one used in Fischer et al.'s study (1,673 versus
6,050 cases); (2) we assumed a 3-fold higher value (i.e. 96
versus 32) for the ratio of outpatient visits to rotavirus
deaths; (3) we used a lower efficacy (i.e. 77% versus 93%
against hospitalization and 78% against outpatient visits)
adjusted for the local genotype distribution; (4) we used a
Markov model, unlike Fischer et al.'s study, distinguishing
between primary and subsequent rotavirus infections and
considering immunity due to wildtype infections. Our
sensitivity analysis results suggest that a significant por-
tion of the differences may be due to the differences in the
key epidemiological parameters. However, further
research to quantify the contribution of each factor to the
discrepancy may provide more insight into the impact of
different sources of uncertainty on the cost-effectiveness
rotavirus vaccines.
Our study has several limitations. First, although our
model attempted to reflect the natural history of rotavirus
infection more comprehensively, we did not model sea-
sonality or coinfection by different serotypes of rotavirus.
Second, local epidemiological data quality was variable,
and country-specific data were not always available. We
had to estimate values of some key epidemiological
parameters (e.g., genotype-specific vaccine efficacy and
incidence rates of primary and subsequent rotavirus infec-
tions) based on data from other countries. Third, our
model is static and does not capture the effects of vaccina-
tion on the force of infection (the rate at which susceptible
individuals get infected) in populations over time. Fourth,
we did not include Rotateq®, another new rotavirus vac-
cine, in our analysis. Given that Rotateq® can cover more
serotypes circulating in Vietnam, this vaccine may provide
a higher serotype-adjusted vaccine efficacy against severe
rotavirus diseases. However, a majority of the effective-
ness gains from the higher vaccine efficacy may be offset
by higher vaccine costs. Accordingly, we expect similar
results with Rotateq®. Fifth, while we conducted a sensitiv-
ity analysis to explore the impact of waning vaccine-
induced immunity and found an approximate 15%
increase in the cost-effectiveness ratio, we did not explore
the implications of specific relationships and correlations
between natural immunity and vaccine induced immu-
nity within individuals. As better data become available,
these will be important to incorporate to ensure the
impact of vaccination is not overestimated. Finally, it was
not possible to project the potential impact of routine vac-
cination on the serotype distribution of rotavirus. Because
the currently available rotavirus vaccines do not provide
cross-immunity for all serotypes, and because serotypes of
rotavirus are known to vary over time even in the same
country [3], if routine vaccination affects the dynamics of
serotype evolution in some way, future vaccine efficacy
may in turn be affected considerably.
Despite the limitations, our study provides insight into
future research areas for rotavirus disease control using
vaccines. Our analysis highlights that there is a high level
of uncertainty and variability around rotavirus epidemiol-
ogy and vaccine efficacy. For example, in adjusting vaccine
efficacy for the genotype distribution of rotavirus, the gen-
otype distributions differed widely across studies even
within Vietnam [35,37,46], leading to a wide range of
adjusted vaccine efficacy between 46% [37] and 81% [46]
with the base-case rate of 77% [35]. High uncertainty also
exists around the level of immunity by natural infection in
Vietnam, given that no other cohort study comparable to
Velazquez et al.'s study in Mexico [8] (from which we
obtained the estimates of relative risks among various
rotavirus infection outcomes) has been conducted in dif-
ferent settings with different genotype distributions. In
addition, little is known as to how long immunity con-
ferred by vaccines or wild type infections would last. All
these warrant further research on the genotype-specific
vaccine efficacy and possible waning of vaccine immunity
in local settings and more comprehensive surveillances to
monitor potential genotype evolution following vaccine
introduction. Particularly for Vietnam, given that theBMC Public Health 2009, 9:29 http://www.biomedcentral.com/1471-2458/9/29
Page 11 of 12
(page number not for citation purposes)
base-case incremental cost-effectiveness ratio ($540/
DALY averted) was very close to Vietnam's per capita GDP
(~$580), which is often used as a surrogate threshold for
identifying very cost-effective interventions, and that rotavi-
rus vaccines are likely to compete against other childhood
vaccines for limited budget allocations, it may be worth
performing a value of information analysis in order to set
priorities among such future studies. Finally, as our com-
parison exercise with a previous study implies, it may be
worthwhile to examine uncertainty related to different
model type or structure more formally.
Conclusion
In conclusion, introducing rotavirus vaccines would be a
cost-effective public health intervention in Vietnam and
other developing countries with high rotavirus disease
burden. However, given the high uncertainty about vac-
cine efficacy and potential changes in rotavirus epidemi-
ology that might in turn affect rotavirus vaccine efficacy,
further clinical research is warranted and a re-evaluation
of a rotavirus vaccination program from a long-term per-
spective may be necessary as new information emerges.
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